ELIOEarnings•globenewswire•
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sentiment:Neutral (55)
Summary
Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire